The Effect of the Prostate Cancer Foundation Screening Guidelines for Black Men on Intention to Screen in Faith-based Communities
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Texas
-
Houston, Texas, United States, 77030
- MD Anderson Cancer Center
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Study Population
Description
Inclusion Criteria:
- Self-reported identification of Black/ African American
- Willingness to participate in the study with signed and dated informed consent
Exclusion Criteria:
- Non-english proficiency
- Unwillingness to participate in the study or inability to sign and date an informed consent
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Screening
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Other: Prostate Cancer Foundation Screening
Participants will be asked about your views and personal opinions on barriers of prostate cancer screening in the Black community, with a specific focus on Black men in church. Participants will also watch an educational video about prostate cancer and review specialized prostate cancer guidelines for Black men and will be asked to provide feedback about these materials. The focus group will take about 2 hours to complete and will be led by the study Investigator and a research coordinator. A member of the research team will also take notes during the focus group, and the discussion will also be audio recorded and transcribed (written down word for word). Additionally, participant demographic information will be collected (such as your age). |
The focus group will take about 2 hours to complete and will be led by the study Investigator and a research coordinator. A member of the research team will also take notes during the focus group, and the discussion will also be audio recorded and transcribed (written down word for word). Additionally, participant demographic information will be collected (such as your age). |
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Incidence of Adverse Events, Graded According to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Version (v) 5.0
Time Frame: Through study completion, an average of 1 year.
|
Through study completion, an average of 1 year.
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Matthew T Smith, M.D. Anderson Cancer Center
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Estimated)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 2024-1312
- NCI-2025-01043 (Other Identifier: National Cancer Institute)
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.